Basic Information
| RNALocate ID: | RLID:01001305 |
| RNA Symbol: | hsa-miR-21-5p |
| Localization: | Cytoplasm |
RNA Information
| RNA Name: | hsa-miR-21 |
| RNA ID: | miRBase:MIMAT0000076 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 27482754 |
| Tissue/Cell Line: | Breast cancer cells (MCF-7) |
| Method: | Microscopy |
| Condition: | Incubated with the binary system |
| Description: | As shown in Figure 2a, within the first 30 min, there was no obvious fluorescence signal. After 50 min, the red fluorescence of Cy5 emerged in the cytoplasm, and its intensity kept growing with the incubation time until reaching a plateau after 1.5 h (Figure 2a, A1-A6). The recovering of the Cy5 fluorescence indicated the opening of the hairpin structure (MB) on the surface of AuNP probes, and thus demonstrated the existence of the miRNA-21. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01001306 | Cytoplasm | Neural progenitor cells | 21363885 |
| RLID:01001307 | Cytoplasm | Cell line (HeLa) | 21695135 |
| RLID:01001308 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001309 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
| RLID:01001310 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
| RLID:01001311 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001312 | Nucleolus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001313 | Polysome | Human cervical cancer cell line (HeLa) | 25609084 |
| RLID:01001314 | Ribosome | Human glioblastoma cell line (U-87) | 27725160 |
| RLID:11000752 | Apoptotic body | Human umbilical vein endothelial cells | 19996457 |
| RLID:11000753 | Exosome | Lung cancer cell lines (A549|SK-MES) | 22753494 |
| RLID:11000754 | Exosome | Serum | 23224754 |
| RLID:11000755 | Exosome | Cell lines (MCF10A|MCF-7|MDA-MB-231) | 25446899 |
| RLID:11000756 | Exosome | Human cervical carcinoma cell line (HeLa|SiHa) | 25760330 |
| RLID:11000757 | Exosome | NBL cell lines (CHLA-255|IMR-32|SK-N-BE(2)) | 25972604 |
| RLID:11000758 | Exosome | Urine | 26417675 |
| RLID:11000759 | Exosome | Human bronchial epithelial cells | 26525579 |
| RLID:11000760 | Exosome | Urine | 26576778 |
| RLID:11000761 | Exosome | Esophageal cancer cell line (EC9706) | 27035745 |
| RLID:11000762 | Exosome | EBV- and KSHV-negative Burkitt lymphoma cell line (Bjab)|EBV-infected lymphoblastoid cell line (LCL)|KSHV-infected lymphoma cell lines (BCBL-1|TY-1) | 27611973 |
| RLID:11000763 | Exosome | Plasma | 29143228 |
| RLID:11000764 | Exosome | Human cervical cancer cell line (HeLa) | 29492481 |
| RLID:11000765 | Exosome | HNSCC cell line (FaDu) | 29981499 |
| RLID:11000766 | Exosome | Peripheral blood|Portal vein blood | 30561106 |
| RLID:11000767 | Exosome | BC cell lines (HCC70|MCF-7|MDA-MB-231) | 30728048 |
| RLID:11000768 | Exosome | Extracellular vesicles from the medium of HCC cells (SMMC-7721) | 31037150 |
| RLID:11000769 | Exosome | Glioblastoma cells | 19011622 |
| RLID:11000770 | Exosome | Plasma | 19289371 |
| RLID:11000771 | Exosome | Placenta | 19494253 |
| RLID:11000772 | Exosome | Human embryonic kidney cell line (HEK-293) | 20353945 |
| RLID:11000773 | Exosome | Breast cancer cell line (MCF-7) | 20976003 |
| RLID:11000774 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
| RLID:11000775 | Exosome | Ascites fluid|Pleural effusion | 21601258 |
| RLID:11000776 | Exosome | Breast milk | 22211110 |
| RLID:11000777 | Exosome | Colorectal cancer cell lines (HCT-15|SW480|WiDr) | 22895844 |
| RLID:11000778 | Exosome | Brain tissue | 23382797 |
| RLID:11000779 | Exosome | Plasma | 23663360 |
| RLID:11000780 | Exosome | Human mast cell line (HMC-1) | 24009880 |
| RLID:11000781 | Exosome | Plasma | 24130905 |
| RLID:11000782 | Exosome | Human esophageal cancer cell line (EC9706) | 25184951 |
| RLID:11000783 | Extracellular vesicle | HEK-293T cells | 22849433 |
| RLID:11000784 | Microvesicle | Glioblastoma cells | 19011622 |
| RLID:11000785 | Microvesicle | Plasma | 23077538 |
| RLID:11000786 | Microvesicle | Seminal plasma | 23539611 |
| RLID:11000787 | Microvesicle | Follicular fluid | 23666971 |
| RLID:11000788 | Microvesicle | Hepatoma cells | 23771658 |
| RLID:11000789 | Microvesicle | Serum | 24797360 |
| RLID-D:11000013 | Exosome | Blood|B lymphoblastoid cells|Breast milk|Chronic lymphocytic leukemia cells|Colon tissue|Endothelial cells|Epithelial cells|Kidney tissue|Lymphoma tissue|Mast cells|Saliva|Seminal fluid|Tongue tissue | |
| RLID-D:11000275 | Microvesicle | Blood|Breast cell line|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-21-5p | Idiopathic pulmonary fibrosis | MNDR-E-MI-29347 |
| MNDR | hsa-miR-21-5p | Diffuse large b cell lymphoma | MNDR-E-MI-29348 |
| MNDR | hsa-miR-21-5p | Splenic marginal zone lymphoma | MNDR-E-MI-29349 |
| MNDR | hsa-miR-21-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-29350 |
| MNDR | hsa-miR-21-5p | Renal fibrosis | MNDR-E-MI-29351 |
| MNDR | hsa-miR-21-5p | Tongue squamous cell carcinoma | MNDR-E-MI-29352 |
| MNDR | hsa-miR-21-5p | Oral squamous cell carcinoma | MNDR-E-MI-29353 |
| MNDR | hsa-miR-21-5p | Large cell neuroendocrine cancer | MNDR-E-MI-29354 |
| MNDR | hsa-miR-21-5p | Medulloblastoma | MNDR-E-MI-29355 |
| MNDR | hsa-miR-21-5p | B cell lymphoma of malt type | MNDR-E-MI-29356 |
| MNDR | hsa-miR-21-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-29357 |
| MNDR | hsa-miR-21-5p | Lymphoma | MNDR-E-MI-29358 |
| MNDR | hsa-miR-21-5p | Lymphoma non-hodgkin | MNDR-E-MI-29359 |
| MNDR | hsa-miR-21-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-29360 |
| MNDR | hsa-miR-21-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-29361 |
| MNDR | hsa-miR-21-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-29362 |
| MNDR | hsa-miR-21-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-29363 |
| MNDR | hsa-miR-21-5p | Her2-receptor positive breast cancer | MNDR-E-MI-29364 |
| MNDR | hsa-miR-21-5p | Triple negative breast cancer | MNDR-E-MI-29365 |
| MNDR | hsa-miR-21-5p | Acute promyelocytic leukemia | MNDR-E-MI-29366 |
| MNDR | hsa-miR-21-5p | Perlman syndrome | MNDR-E-MI-29367 |
| MNDR | hsa-miR-21-5p | Bone disease | MNDR-E-MI-29368 |
| MNDR | hsa-miR-21-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-29369 |
| MNDR | hsa-miR-21-5p | Thyroid carcinoma anaplastic | MNDR-E-MI-29370 |
| MNDR | hsa-miR-21-5p | Neurofibromatosis 2 | MNDR-E-MI-29371 |
| MNDR | hsa-miR-21-5p | Dermatomyositis | MNDR-E-MI-29372 |
| MNDR | hsa-miR-21-5p | Prostate cancer | MNDR-E-MI-29373 |
| MNDR | hsa-miR-21-5p | Gastric cancer | MNDR-E-MI-29374 |
| MNDR | hsa-miR-21-5p | Gastric lymphoma | MNDR-E-MI-29375 |
| MNDR | hsa-miR-21-5p | Alzheimer disease | MNDR-E-MI-29376 |
| MNDR | hsa-miR-21-5p | Hypertension | MNDR-E-MI-29377 |
| MNDR | hsa-miR-21-5p | Intracranial aneurysm | MNDR-E-MI-29378 |
| MNDR | hsa-miR-21-5p | Bladder cancer | MNDR-E-MI-29379 |
| MNDR | hsa-miR-21-5p | Esophageal carcinoma | MNDR-E-MI-29380 |
| MNDR | hsa-miR-21-5p | Sarcoma | MNDR-E-MI-29381 |
| MNDR | hsa-miR-21-5p | Heart disease | MNDR-E-MI-29382 |
| MNDR | hsa-miR-21-5p | Dysautonomia familial | MNDR-E-MI-29383 |
| MNDR | hsa-miR-21-5p | Duchenne muscular dystrophy | MNDR-E-MI-29384 |
| MNDR | hsa-miR-21-5p | Facioscapulohumeral muscular dystrophy | MNDR-E-MI-29385 |
| MNDR | hsa-miR-21-5p | Seizures | MNDR-E-MI-29386 |
| MNDR | hsa-miR-21-5p | Head and neck cancer | MNDR-E-MI-29387 |
| MNDR | hsa-miR-21-5p | Dengue disease | MNDR-E-MI-29388 |
| MNDR | hsa-miR-21-5p | Malaria | MNDR-E-MI-29389 |
| MNDR | hsa-miR-21-5p | Leukemia | MNDR-E-MI-29390 |
| MNDR | hsa-miR-21-5p | Vestibular schwannoma | MNDR-E-MI-29391 |
| MNDR | hsa-miR-21-5p | Cardiovascular disease | MNDR-E-MI-29392 |
| MNDR | hsa-miR-21-5p | Moyamoya disease | MNDR-E-MI-29393 |
| MNDR | hsa-miR-21-5p | Brain cancer | MNDR-E-MI-29394 |
| MNDR | hsa-miR-21-5p | Uterine fibroid | MNDR-E-MI-29395 |
| MNDR | hsa-miR-21-5p | Lung cancer | MNDR-E-MI-29396 |
| MNDR | hsa-miR-21-5p | Giant cell arteritis | MNDR-E-MI-29397 |
| MNDR | hsa-miR-21-5p | Kawasaki disease | MNDR-E-MI-29398 |
| MNDR | hsa-miR-21-5p | Tuberous sclerosis | MNDR-E-MI-29399 |
| MNDR | hsa-miR-21-5p | Eosinophilic esophagitis | MNDR-E-MI-29400 |
| MNDR | hsa-miR-21-5p | Down syndrome | MNDR-E-MI-29401 |
| MNDR | hsa-miR-21-5p | Fragile x syndrome | MNDR-E-MI-29402 |
| MNDR | hsa-miR-21-5p | Parkinson disease | MNDR-E-MI-29403 |
| MNDR | hsa-miR-21-5p | Colon carcinoma | MNDR-E-MI-29404 |
| MNDR | hsa-miR-21-5p | Breast cancer | MNDR-E-MI-29405 |
| MNDR | hsa-miR-21-5p | Squamous cell carcinoma | MNDR-E-MI-29406 |
| MNDR | hsa-miR-21-5p | Vascular diseases | MNDR-E-MI-29407 |
| MNDR | hsa-miR-21-5p | Thyroid cancer | MNDR-E-MI-29408 |
| MNDR | hsa-miR-21-5p | Pituitary neoplasms | MNDR-E-MI-29409 |
| MNDR | hsa-miR-21-5p | Pancreatic cancer | MNDR-E-MI-29410 |
| MNDR | hsa-miR-21-5p | HCV | MNDR-E-MI-29411 |
| MNDR | hsa-miR-21-5p | Melanoma | MNDR-E-MI-29412 |
| MNDR | hsa-miR-21-5p | Atherosclerosis | MNDR-E-MI-29413 |
| MNDR | hsa-miR-21-5p | Rectal cancer | MNDR-E-MI-29414 |
| MNDR | hsa-miR-21-5p | Rectum cancer | MNDR-E-MI-29415 |
| MNDR | hsa-miR-21-5p | Rectum adenocarcinoma | MNDR-E-MI-29416 |
| MNDR | hsa-miR-21-5p | Nephroblastoma | MNDR-E-MI-29417 |
| MNDR | hsa-miR-21-5p | Colon cancer | MNDR-E-MI-29418 |
| MNDR | hsa-miR-21-5p | Ischemic attack transient | MNDR-E-MI-29419 |
| MNDR | hsa-miR-21-5p | Colon adenocarcinoma | MNDR-E-MI-29420 |
| MNDR | hsa-miR-21-5p | Multiple sclerosis | MNDR-E-MI-29421 |
| MNDR | hsa-miR-21-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-29422 |
| MNDR | hsa-miR-21-5p | Familial ovarian cancer | MNDR-E-MI-29423 |
| MNDR | hsa-miR-21-5p | Prostate adenocarcinoma | MNDR-E-MI-29424 |
| MNDR | hsa-miR-21-5p | Laryngeal carcinoma | MNDR-E-MI-29425 |
| MNDR | hsa-miR-21-5p | Kidney cancer | MNDR-E-MI-29426 |
| MNDR | hsa-miR-21-5p | Asthma | MNDR-E-MI-29427 |
| MNDR | hsa-miR-21-5p | Laryngeal squamous cell carcinoma | MNDR-E-MI-29428 |
| MNDR | hsa-miR-21-5p | Carcinoma ductal breast | MNDR-E-MI-29429 |
| MNDR | hsa-miR-21-5p | Breast malignant phyllodes tumor | MNDR-E-MI-29430 |
| MNDR | hsa-miR-21-5p | Acute kidney injury | MNDR-E-MI-29431 |
| MNDR | hsa-miR-21-5p | Glioblastoma | MNDR-E-MI-29432 |
| MNDR | hsa-miR-21-5p | Astrocytoma | MNDR-E-MI-29433 |
| MNDR | hsa-miR-21-5p | Glioma | MNDR-E-MI-29434 |
| MNDR | hsa-miR-21-5p | Oligodendroglioma | MNDR-E-MI-29435 |
| MNDR | hsa-miR-21-5p | Central nervous system lymphoma | MNDR-E-MI-29436 |
| MNDR | hsa-miR-21-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-29437 |
| MNDR | hsa-miR-21-5p | Epilepsy temporal lobe | MNDR-E-MI-29438 |
| MNDR | hsa-miR-21-5p | Osteosarcoma | MNDR-E-MI-29439 |
| MNDR | hsa-miR-21-5p | Coronary artery disease | MNDR-E-MI-29440 |
| MNDR | hsa-miR-21-5p | Inclusion body myositis | MNDR-E-MI-29441 |
| MNDR | hsa-miR-21-5p | Breast carcinoma | MNDR-E-MI-29442 |
| MNDR | hsa-miR-21-5p | Pancreatic ductal adenocarcinoma | MNDR-E-MI-29443 |
| MNDR | hsa-miR-21-5p | Infarction middle cerebral artery | MNDR-E-MI-29444 |
| MNDR | hsa-miR-21-5p | Meningioma | MNDR-E-MI-29445 |
| MNDR | hsa-miR-21-5p | Liver cancer | MNDR-E-MI-29446 |
| MNDR | hsa-miR-21-5p | Uterine cancer | MNDR-E-MI-29447 |
| MNDR | hsa-miR-21-5p | Cervical adenocarcinoma | MNDR-E-MI-29448 |
| MNDR | hsa-miR-21-5p | Gastric adenocarcinoma | MNDR-E-MI-29449 |
| MNDR | hsa-miR-21-5p | Cervical squamous carcinoma | MNDR-E-MI-29450 |
| MNDR | hsa-miR-21-5p | Pituitary adenoma | MNDR-E-MI-29451 |
| MNDR | hsa-miR-21-5p | Lung squamous cell carcinoma | MNDR-E-MI-29452 |
| MNDR | hsa-miR-21-5p | Carcinoma lung non-small-cell | MNDR-E-MI-29453 |
| MNDR | hsa-miR-21-5p | Lung adenocarcinoma | MNDR-E-MI-29454 |
| MNDR | hsa-miR-21-5p | Adrenocortical cancer | MNDR-E-MI-29455 |
| MNDR | hsa-miR-21-5p | Thyroid carcinoma | MNDR-E-MI-29456 |
| MNDR | hsa-miR-21-5p | Papillary thyroid carcinoma | MNDR-E-MI-29457 |
| MNDR | hsa-miR-21-5p | Thyroid medullary carcinoma | MNDR-E-MI-29458 |
| MNDR | hsa-miR-21-5p | Bladder urothelial carcinoma | MNDR-E-MI-29459 |
| MNDR | hsa-miR-21-5p | Pancreatic adenocarcinoma | MNDR-E-MI-29460 |
| MNDR | hsa-miR-21-5p | Intrastent restenosis | MNDR-E-MI-29461 |
| MNDR | hsa-miR-21-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-29462 |
| MNDR | hsa-miR-21-5p | Carcinoma renal cell | MNDR-E-MI-29463 |
| MNDR | hsa-miR-21-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-29464 |
| MNDR | hsa-miR-21-5p | Clear cell renal cell cancer | MNDR-E-MI-29465 |
| MNDR | hsa-miR-21-5p | Large cell carcinoma | MNDR-E-MI-29466 |
| MNDR | hsa-miR-21-5p | Biliary tract cancer | MNDR-E-MI-29467 |
| MNDR | hsa-miR-21-5p | Adenocarcinoma of esophagus | MNDR-E-MI-29468 |
| MNDR | hsa-miR-21-5p | Intrahepatic cholangiocarcinoma | MNDR-E-MI-29469 |
| MNDR | hsa-miR-21-5p | Cholangiocarcinoma | MNDR-E-MI-29470 |
| MNDR | hsa-miR-21-5p | Esophageal cancer | MNDR-E-MI-29471 |
| MNDR | hsa-miR-21-5p | Liver cirrhosis | MNDR-E-MI-29472 |
| MNDR | hsa-miR-21-5p | Lung small cell carcinoma | MNDR-E-MI-29473 |
| MNDR | hsa-miR-21-5p | Stomach carcinoma | MNDR-E-MI-29474 |
| MNDR | hsa-miR-21-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-29475 |
| MNDR | hsa-miR-21-5p | T acute lymphoblastic leukemia | MNDR-E-MI-29476 |
| MNDR | hsa-miR-21-5p | Acute t cell leukemia | MNDR-E-MI-29477 |
| MNDR | hsa-miR-21-5p | Malignant peripheral nerve sheath tumor | MNDR-E-MI-29478 |
| MNDR | hsa-miR-21-5p | Heart failure | MNDR-E-MI-29479 |
| MNDR | hsa-miR-21-5p | Fibromyalgia | MNDR-E-MI-29480 |
| MNDR | hsa-miR-21-5p | Cowden disease | MNDR-E-MI-29481 |
| MNDR | hsa-miR-21-5p | Breast invasive carcinoma | MNDR-E-MI-29482 |
| MNDR | hsa-miR-21-5p | Endometrioid endometrial cancer | MNDR-E-MI-29483 |
| MNDR | hsa-miR-21-5p | Hepatocellular carcinoma | MNDR-E-MI-29484 |
| MNDR | hsa-miR-21-5p | Familiar ovarian carcinoma | MNDR-E-MI-29485 |
| MNDR | hsa-miR-21-5p | B-cell lymphoma | MNDR-E-MI-29486 |
| MNDR | hsa-miR-21-5p | Rheumatoid arthritis | MNDR-E-MI-29487 |
| MNDR | hsa-miR-21-5p | T-cell leukemia | MNDR-E-MI-29488 |
| MNDR | hsa-miR-21-5p | Cervical carcinoma | MNDR-E-MI-29489 |
| MNDR | hsa-miR-21-5p | Neuroblastoma | MNDR-E-MI-29490 |
| MNDR | hsa-miR-21-5p | Chronic kidney disease | MNDR-E-MI-29491 |
| MNDR | hsa-miR-21-5p | Barrett's adenocarcinoma | MNDR-E-MI-29492 |
| MNDR | hsa-miR-21-5p | Periodontitis | MNDR-E-MI-29493 |
| MNDR | hsa-miR-21-5p | Chronic fatigue syndrome | MNDR-E-MI-29494 |
| MNDR | hsa-miR-21-5p | Chronic myelogenous leukemia | MNDR-E-MI-29495 |
| MNDR | hsa-miR-21-5p | Oropharynx cancer | MNDR-E-MI-29496 |
| MNDR | hsa-miR-21-5p | Hodgkin lymphoma | MNDR-E-MI-29497 |
| MNDR | hsa-miR-21-5p | Ulcerative colitis | MNDR-E-MI-29498 |
| MNDR | hsa-miR-21-5p | Burkitt lymphoma | MNDR-E-MI-29499 |
| MNDR | hsa-miR-21-5p | Mouth neoplasms | MNDR-E-MI-29500 |
| MNDR | hsa-miR-21-5p | Cholesteatoma | MNDR-E-MI-29501 |
| MNDR | hsa-miR-21-5p | Crohn disease | MNDR-E-MI-29502 |
| MNDR | hsa-miR-21-5p | Tonsil cancer | MNDR-E-MI-29503 |
| MNDR | hsa-miR-21-5p | Neuromyelitis optica | MNDR-E-MI-29504 |
| MNDR | hsa-miR-21-5p | Systemic lupus erythematosus | MNDR-E-MI-29505 |
| MNDR | hsa-miR-21-5p | Acute myelogenous leukemia | MNDR-E-MI-29506 |
| MNDR | hsa-miR-21-5p | Colorectal cancer | MNDR-E-MI-29507 |
| MNDR | hsa-miR-21-5p | Diabetes mellitus | MNDR-E-MI-29508 |
| MNDR | hsa-miR-21-5p | Type 2 diabetes mellitus | MNDR-E-MI-29509 |
| MNDR | hsa-miR-21-5p | Brain disease | MNDR-E-MI-29510 |
| MNDR | hsa-miR-21-5p | Multiple myeloma | MNDR-E-MI-29511 |
| MNDR | hsa-miR-21-5p | Acute lymphocytic leukemia | MNDR-E-MI-29512 |
| MNDR | hsa-miR-21-5p | Hyaloideoretinal degeneration of wagner | MNDR-E-MI-29513 |
| MNDR | hsa-miR-21-5p | Ovarian epithelial cancer | MNDR-E-MI-29514 |
| MNDR | hsa-miR-21-5p | Esophageal squamous cell carcinoma | MNDR-E-MI-29515 |
| MNDR | hsa-miR-21-5p | Uterine cervical neoplasms | MNDR-E-MI-29516 |
| MNDR | hsa-miR-21-5p | Cicatrix | MNDR-E-MI-29517 |
| MNDR | hsa-miR-21-5p | Diabetic nephropathies | MNDR-E-MI-29518 |
| MNDR | hsa-miR-21-5p | Ependymoma | MNDR-E-MI-29519 |
| MNDR | hsa-miR-21-5p | Cardiomegaly | MNDR-E-MI-29520 |
| MNDR | hsa-miR-21-5p | Inflammation | MNDR-E-MI-29521 |
| MNDR | hsa-miR-21-5p | Nasopharyngeal cancer | MNDR-E-MI-29522 |
| MNDR | hsa-miR-21-5p | Prostatic neoplasms | MNDR-E-MI-29523 |
| MNDR | hsa-miR-21-5p | Pseudorabies | MNDR-E-MI-29524 |
| MNDR | hsa-miR-21-5p | Wounds and injuries | MNDR-E-MI-29525 |
| MNDR | hsa-miR-21-5p | Polymyositis | MNDR-E-MI-29526 |
| MNDR | hsa-miR-21-5p | Epstein-barr virus infections | MNDR-E-MI-29527 |
| MNDR | hsa-miR-21-5p | Cerebral hemorrhage traumatic | MNDR-E-MI-29528 |
| MNDR | hsa-miR-21-5p | Subarachnoid hemorrhage traumatic | MNDR-E-MI-29529 |
| MNDR | hsa-miR-21-5p | Brain injury chronic | MNDR-E-MI-29530 |
| MNDR | hsa-miR-21-5p | Intracranial hemorrhage hypertensive | MNDR-E-MI-29531 |
| MNDR | hsa-miR-21-5p | Pituitary acth hypersecretion | MNDR-E-MI-29532 |
| MNDR | hsa-miR-21-5p | Stroke lacunar | MNDR-E-MI-29533 |
| MNDR | hsa-miR-21-5p | Non-alcoholic fatty liver disease | MNDR-E-MI-29534 |
| MNDR | hsa-miR-21-5p | Barrett's carcinogenesis | MNDR-E-MI-29535 |
| MNDR | hsa-miR-21-5p | Brain metastasis | MNDR-E-MI-29536 |
| MNDR | hsa-miR-21-5p | Breast cancer her3+ negative | MNDR-E-MI-29537 |
| MNDR | hsa-miR-21-5p | Duke A | MNDR-E-MI-29538 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ABCB1 | Homo sapiens | RR00022780 |
TOP